Treatment of depression or generalized anxiety disorder
AssigneePfizer Inc.
InventorGene Michael Bright
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for treating a disorder that is treated by modulation of serotonergic neurotransmission comprising administering (7S,9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido-[1,2-a]pyrazine and sertraline is disclosed.
Claims3
A pharmaceutical composition for treating a disorder or condition that can be treated or prevented by modulating serotonergic neurotransmission in a mammal, comprising:
- a) a pharmaceutically acceptable carrier;
- b) (7S,9aS)-cis-2Benzo[d]isoxazol-3-yl-7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido-[1,2-a]pyrazine;
- and
- c) sertraline or a pharmaceutically acceptable salt thereof;
- wherein the amount of b) and the amount of c) are such that the combination is effective in treating such disorder or condition.
A method for treating a disorder or condition that can be treated by modulating serotonergic neurotransmisslon in a mammal, comprising administering to a mammal requiring such treatment or prevention:
- a) (7S,9aS)-cis-2Benzo[d]isoxazol-3-yl-7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido-[1,2-a]pyrazine;
- and
- b) sertraline or a pharmaceutically acceptable salt thereof;
- wherein the amount of a) and the amount of b) are such that the combination is effective in treating such disorder or condition.
A method for treating a disorder or condition selected from depression or generalized anxiety disorder in a mammal, comprising administering to a mammal requiring such treatment:
- a) (7S,9aS)-cis-2Benzo[d]isoxazol-3-yl-7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido-[1,2-a]pyrazine;
- and
- b) sertraline or a pharmaceutically acceptable salt thereof;
- wherein the amount of a) and the amount of b) are such that the combination is effective in treating such disorder or condition.
Dependencies are inferred from the claim text.